drugset / Trial / NCT00001422
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
Phase 2
Completed
20 enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Treatment
Summary
This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic drug.
Timeline
- Start
- 1995-06
- Primary completion
- —
- Completion
- 2000-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |